These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 18790768)

  • 21. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
    Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.
    Jang GH; Kim NY; Lee M
    Mol Cell Biochem; 2015 Aug; 406(1-2):53-62. PubMed ID: 25912549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.
    Wen X; Han M; Hosoya M; Toshima R; Onishi M; Fujii T; Yamaguchi S; Kato S
    Anticancer Res; 2024 Jun; 44(6):2349-2358. PubMed ID: 38821628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
    Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
    Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF
    Feng L; Li J; Bu X; Zuo Y; Shen L; Qu X
    Biochem Biophys Res Commun; 2020 Mar; 524(1):28-35. PubMed ID: 31980175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
    Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
    Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RAF265 inhibits the growth of advanced human melanoma tumors.
    Su Y; Vilgelm AE; Kelley MC; Hawkins OE; Liu Y; Boyd KL; Kantrow S; Splittgerber RC; Short SP; Sobolik T; Zaja-Milatovic S; Dahlman KB; Amiri KI; Jiang A; Lu P; Shyr Y; Stuart DD; Levy S; Sosman JA; Richmond A
    Clin Cancer Res; 2012 Apr; 18(8):2184-98. PubMed ID: 22351689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
    Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
    Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.
    Lázár V; Ecsedi S; Szöllosi AG; Tóth R; Vízkeleti L; Rákosy Z; Bégány A; Adány R; Balázs M
    Mod Pathol; 2009 Oct; 22(10):1367-78. PubMed ID: 19633643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
    Xiao J; Egger ME; McMasters KM; Hao H
    BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells.
    Hu R; Aplin AE
    Pigment Cell Melanoma Res; 2010 Apr; 23(2):201-9. PubMed ID: 20067552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation.
    Ikediobi ON; Reimers M; Durinck S; Blower PE; Futreal AP; Stratton MR; Weinstein JN
    Mol Cancer Ther; 2008 Jun; 7(6):1337-46. PubMed ID: 18524847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
    Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
    Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
    J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.
    Yancovitz M; Litterman A; Yoon J; Ng E; Shapiro RL; Berman RS; Pavlick AC; Darvishian F; Christos P; Mazumdar M; Osman I; Polsky D
    PLoS One; 2012; 7(1):e29336. PubMed ID: 22235286
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Braf V600E mutation in melanoma: translational current scenario.
    Guadarrama-Orozco JA; Ortega-Gómez A; Ruiz-García EB; Astudillo-de la Vega H; Meneses-García A; Lopez-Camarillo C
    Clin Transl Oncol; 2016 Sep; 18(9):863-71. PubMed ID: 26825657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.